This is the date to focus on. P2 interim results will be announced on their schizophrenia drug. Prospective investors should look at the company presentation. Below the radar because it is an Israeli company and has only recently been listed on NASDAQ. Company says it bridges the development gap. Not enough capital in israel to advance all the promising science. Company in licenses compounds. multiple shots on goal.
Wrong. We get interim data from P3 for their schizophrenia drug (not P2). The efficacy data will kept blinded, but we get an information about the number of patients needed to conclude the study. This data is a strong hint how well the study performs and how good the efficacy data are.
I really find this company to be undervalued. Multiple candidates for diverse conditions. Acquiring promising molecules and products straight from the University / Academia to clinical. If BL-1020 shows significant statistical efficacy (only 100 more patients needed) this company can get more visibility and recognition from the marketplace.